Formulation Development
Biora Therapeutics Announces Submission of IND Application for BT-600 Program Featuring NaviCap Ingestible Drug Delivery Device
Biora Therapeutics, Inc. recently announced submission of an Investigational New Drug (IND) application with the US FDA that supports the next phase of development of…
Replay Announces Partnership Between Syena & JURA Bio to Advance T Cell Receptor NK Therapies in Cancer
Replay recently announced a research collaboration between JURA Bio and Syena to develop T cell receptor (TCR) based therapies. “JURA Bio’s highly differentiated TCR discovery…
Bora Collaborates With Sunway Biotech to Launch Global Nutraceuticals Offering
Bora Health, a global design, development and distribution partner of pharmaceuticals and health foods and part of the Bora group, recently announced its merged with Sunway Biotech, a leading ingredients manufacturer and….
Revolo Biotherapeutics Announces Completion of Phase 1 Multiple Ascending Dose Clinical Trial of Immune-Resetting Drug Candidate
Revolo Biotherapeutics recently announced the completion of a Phase 1 multiple ascending dose (MAD) clinical trial evaluating the safety and tolerability of the company’s immune-resetting…
Oxford Biomedica & Institut Mérieux Enter Exclusive Negotiations With Respect to Proposed Acquisition by Oxford Biomedica of ABL Europe From Institut Mérieux as Part of Pure-Play CDMO Transformation
Oxford Biomedica plc and Institut Mérieux SA recently announced they have entered into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of…
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating Investigational T Cell Vaccine for the Prevention of HIV
Vir Biotechnology, Inc. recently announced the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity, and immunogenicity of VIR-1388, an investigational novel T cell vaccine for….
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, Plus GSK’s Immunotherapy in Clear-Cell Ovarian Cancer
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A….
ALSA Ventures Launches Novel Gene Therapy Portfolio Company Axovia Therapeutics
ALSA Ventures recently announced the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd. Axovia is developing the…
Rhythm Pharmaceuticals Receives Orphan Drug Designation for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. recently announced the European Medicines Agency (EMA) has issued a positive opinion on the company’s orphan drug designation request for setmelanotide as…
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Trioxide Treatment Supporting Clinical Trial for Systemic Sclerosis
BioSenic recently announced publication of data providing additional key indications of its lead API (Active Pharmaceutical Ingredient) arsenic trioxide (ATO) to treat systemic sclerosis (SSc)…
Samsung Biologics Announces Expanded Strategic Agreement With Bristol Myers Squibb
Samsung Biologics recently announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug….
BioNTech & CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development & Support CEPI’s 100 Days Mission
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) recently announced a strategic partnership to advance mRNA-based vaccine candidates with the development of….
Orchard Therapeutics Announces Acceptance of BLA for OTL-200 in MLD; Receives Priority Review
Orchard Therapeutics recently announced the US FDA has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)
Rani Therapeutics Holdings, Inc. recently announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered…
POINT Biopharma & Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
POINT Biopharma Global Inc. and Athebio AG recently announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (Radio-DARPins). DARPins are an attractive…
New Collaboration With Stevanato Group to Elevate mRNA Production With Nfinity Platform
Quantoom Biosciences recently announced a new collaboration with Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of….
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod From Sanofi
First Wave to develop and repurpose Capeserod for gastrointestinal (GI) indications based on AI-empowered analyses, expanding the company’s GI-focused pipeline….
Anavex’s Phase 2b/3 Trial of Blarcamesine in Patients With Alzheimer’s Disease Shows Robust Clinical Efficacy & Slows Neurodegeneration
Anavex Life Sciences Corp. recently announced that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug…
Evoke Pharma Receives Notice of Allowance from USPTO for First & Only FDA-Approved Nasal Formulation of Metoclopramide Commercially Available in the US
Evoke Pharma, Inc. recently announced it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application No.…
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
Hepion Pharmaceuticals, Inc. recently announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from….
